About TURALIO

TURALIO was studied in the largest clinical trial of an oral treatment for TGCT

TURALIO is a medication that blocks some of the inflammation signals that can cause TGCT tumors. TURALIO was studied in a clinical trial of 120 patients who had advanced TGCT, for whom surgery was not recommended. For 24 weeks, half of the patients in the trial were given TURALIO and half were given a placebo.* After 24 weeks, patients in both groups were offered continued treatment with TURALIO.

The study tested whether TURALIO was able to:
down-arrow

Eliminate or
reduce tumor size

down-arrow

Increase
joint movement

Although tested, TURALIO has not been shown to improve physical functioning or the ability to
perform daily activities.

*A placebo (or “sugar pill”) contains no active ingredient and provides no medical effect.

The clinical trial included TGCT in both the upper and lower body

The image below shows the locations of patients’ tumors in the trial (120 patients).

Upper Body
Lower Body

Of patients in the trial:

88%

(105 of 120 patients) had

DIFFUSE TGCT
47%

(56 of 120 patients) had

NO SURGERY FOR TGCT
Upper Body
Lower Body

Of patients in the trial:

88%

(105 of 120 patients) had

DIFFUSE TGCT
47%

(56 of 120 patients) had

NO SURGERY FOR TGCT

TURALIO: Clinically proven to help reduce tumor size

Two measurements tracked whether TURALIO was able to reduce the size of the patients' tumors. One measured the length of the tumor. The other measured the volume of the tumor (the amount of space the tumor filled within the joint).

after taking TURALIO for 25 weeks

Measuring tumor by length

A reduction in tumor size meant that tumor length
decreased by at least 30%.

Of the patients taking TURALIO:

  • 23% (14 of 61) had their tumors reduce in length by 30% or more
  • 15% (9 of 61) had their tumors disappear completely

None of the patients taking placebo experienced a reduction in tumor length.

after taking TURALIO for 25 weeks

Measuring tumor by volume

A reduction in tumor size meant that tumor volume
decreased by at least 50%.

Of the patients taking TURALIO:

  • 51% (31 of 61) had their tumors reduce in volume by 50% or more
  • 5% (3 of 61) had their tumors disappear completely

None of the patients taking placebo experienced a reduction in tumor volume.

Responses improved with time

Within about 38 months, more than half of the patients taking TURALIO had reductions in tumor size:

  • 62% of patients (38 of 61) had a reduction in tumor length, and 66% of patients (40 of 61) had a reduction in tumor volume.
  • Because the clinical study did not plan to measure responses over time, it was considered exploratory. This means that it was not possible to tell if TURALIO had caused the responses to last as long as they did or if these long responses were due to chance.
  • Individual responses may vary.

TURALIO improved range of motion.

After a clinical assessment at 25 weeks, results showed that patients taking TURALIO had significantly improved range of motion compared with patients taking placebo.

Information was not available for 16 of 61 patients in the TURALIO arm and 16 of 59 patients in the placebo arm. It was not possible to know if the patients with data missing were experiencing worse range of motion than patients with data available.

Range of motion is a measure of the amount of movement possible in a specific joint.

Please see Important Safety Information below and learn more about preparing for treatment.
Learn more about the first and only treatment of its kind